DE69712610T2 - Erythramicin-derivate, ihre verfahren zur herstellung und ihre verwendung als arzneimittel - Google Patents

Erythramicin-derivate, ihre verfahren zur herstellung und ihre verwendung als arzneimittel

Info

Publication number
DE69712610T2
DE69712610T2 DE69712610T DE69712610T DE69712610T2 DE 69712610 T2 DE69712610 T2 DE 69712610T2 DE 69712610 T DE69712610 T DE 69712610T DE 69712610 T DE69712610 T DE 69712610T DE 69712610 T2 DE69712610 T2 DE 69712610T2
Authority
DE
Germany
Prior art keywords
erythramicin
derivatives
production
medicinal products
medicinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69712610T
Other languages
German (de)
English (en)
Other versions
DE69712610D1 (de
Inventor
Constantin Agouridas
Jean-Francois Chantot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Application granted granted Critical
Publication of DE69712610D1 publication Critical patent/DE69712610D1/de
Publication of DE69712610T2 publication Critical patent/DE69712610T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
DE69712610T 1996-02-28 1997-02-27 Erythramicin-derivate, ihre verfahren zur herstellung und ihre verwendung als arzneimittel Expired - Lifetime DE69712610T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9602472A FR2745290B1 (fr) 1996-02-28 1996-02-28 Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
PCT/FR1997/000351 WO1997031929A1 (fr) 1996-02-28 1997-02-27 Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments

Publications (2)

Publication Number Publication Date
DE69712610D1 DE69712610D1 (de) 2002-06-20
DE69712610T2 true DE69712610T2 (de) 2002-11-28

Family

ID=9489659

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69712610T Expired - Lifetime DE69712610T2 (de) 1996-02-28 1997-02-27 Erythramicin-derivate, ihre verfahren zur herstellung und ihre verwendung als arzneimittel

Country Status (31)

Country Link
US (1) US6096714A (fr)
EP (1) EP0885234B1 (fr)
JP (1) JP4102440B2 (fr)
KR (1) KR100486053B1 (fr)
CN (1) CN1168734C (fr)
AP (1) AP952A (fr)
AR (1) AR005999A1 (fr)
AT (1) ATE217633T1 (fr)
AU (1) AU716204B2 (fr)
BG (1) BG63207B1 (fr)
BR (1) BR9707709B1 (fr)
CZ (1) CZ293893B6 (fr)
DE (1) DE69712610T2 (fr)
DK (1) DK0885234T3 (fr)
EA (1) EA001376B1 (fr)
EE (1) EE9800265A (fr)
ES (1) ES2176698T3 (fr)
FR (1) FR2745290B1 (fr)
HU (1) HU227567B1 (fr)
IL (1) IL125622A (fr)
NO (1) NO983955D0 (fr)
NZ (1) NZ331600A (fr)
OA (1) OA10845A (fr)
PL (1) PL191736B1 (fr)
PT (1) PT885234E (fr)
SK (1) SK118498A3 (fr)
TR (1) TR199801713T2 (fr)
UA (1) UA58504C2 (fr)
WO (1) WO1997031929A1 (fr)
YU (1) YU37098A (fr)
ZA (1) ZA971659B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9649598A (en) * 1997-10-29 1999-05-17 Taisho Pharmaceutical Co., Ltd. Erythromycin a, 11,12-carbamate derivatives
WO1999021870A1 (fr) * 1997-10-29 1999-05-06 Taisho Pharmaceutical Co., Ltd. Derives de l'erythromycine a 11,12-carbamate
FR2780977B1 (fr) * 1998-07-09 2000-09-01 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
JP4573925B2 (ja) * 1998-07-09 2010-11-04 アベンティス・ファーマ・ソシエテ・アノニム 新規のエリスロマイシン誘導体、その製造方法及びその薬剤としての使用
FR2792637B1 (fr) * 1999-04-26 2001-06-01 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2781484B1 (fr) * 1998-07-21 2001-08-10 Hoechst Marion Roussel Inc Nouveaux derives de la 6-deoxy erythromycine, leur procede de preparation et leur application comme medicaments
CZ20012675A3 (cs) 1999-01-27 2002-04-17 Pfizer Products Inc. Ketolidová antibiotika
WO2000071557A1 (fr) * 1999-05-24 2000-11-30 Pfizer Products Inc. Derives de 13-methyl-erythromycine
AU6316400A (en) * 1999-08-06 2001-03-05 Taisho Pharmaceutical Co., Ltd. Erythromycin a derivatives
WO2001010878A1 (fr) * 1999-08-06 2001-02-15 Taisho Pharmaceutical Co., Ltd. Derives d'erythromycine a
WO2001010880A1 (fr) * 1999-08-06 2001-02-15 Taisho Pharmaceutical Co., Ltd. Derives d'erythromycine a
EP1146051A3 (fr) * 2000-04-10 2001-10-31 Pfizer Products Inc. Dérivées de l' érythromycine A
US20020115621A1 (en) * 2000-08-07 2002-08-22 Wei-Gu Su Macrolide antibiotics
ITMI20021726A1 (it) 2002-08-01 2004-02-02 Zambon Spa Macrolidi ad attivita' antiinfiammatoria.
US7601695B2 (en) 2003-03-10 2009-10-13 Optimer Pharmaceuticals, Inc. Antibacterial agents
WO2005007143A2 (fr) * 2003-07-14 2005-01-27 The Board Of Trustees Of The University Of Illinois Procede pour traiter la tuberculose
WO2007069264A2 (fr) * 2005-12-15 2007-06-21 Alembic Limited Nouveaux composes
AU2008316830B2 (en) * 2007-10-25 2016-03-17 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
DK2358379T3 (en) * 2008-10-24 2016-03-07 Cempra Pharmaceuticals Inc BIOFORSVAR USING TRIAZOLHOLDIGE macrolides
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
AU2010292010B2 (en) 2009-09-10 2016-01-07 Cempra Pharmaceuticals, Inc. Methods for treating malaria, tuberculosis and MAC diseases
CA2793884C (fr) 2010-03-22 2019-09-10 Cempra Pharmaceuticals, Inc. Formes cristallines d'un macrolide et leurs utilisations
DK2571506T3 (en) 2010-05-20 2017-08-28 Cempra Pharmaceuticals Inc PROCEDURES FOR THE MANUFACTURE OF MACROLIDES AND KETOLIDES AND INTERMEDIATES
EP2613630A4 (fr) 2010-09-10 2014-01-15 Cempra Pharmaceuticals Inc Fluorocétolides formant des liaisons hydrogène pour traiter les maladies
WO2013148891A1 (fr) 2012-03-27 2013-10-03 Cempra Pharmaceuticals, Inc. Formulations parentérales pour l'administration d'antibiotiques macrolides
US9861616B2 (en) 2013-03-14 2018-01-09 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
CN105188712A (zh) 2013-03-15 2015-12-23 森普拉制药公司 用于制备大环内酯抗菌剂的收敛方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US487411A (en) * 1892-12-06 Island
IL99995A (en) * 1990-11-21 1997-11-20 Roussel Uclaf Erythromycin derivatives, their preparation and pharmaceutical compositions containing them
US5444031A (en) * 1993-01-21 1995-08-22 Calgon Carbon Corporation Process for making catalytic carbon
FR2727969B1 (fr) * 1994-12-09 1997-01-17 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments

Also Published As

Publication number Publication date
EA199800768A1 (ru) 1999-02-25
CZ293893B6 (cs) 2004-08-18
AP9801318A0 (en) 1998-09-30
WO1997031929A1 (fr) 1997-09-04
HUP9902576A3 (en) 2001-03-28
PL328608A1 (en) 1999-02-01
AU716204B2 (en) 2000-02-24
BG63207B1 (bg) 2001-06-29
OA10845A (fr) 2003-02-05
DK0885234T3 (da) 2002-08-26
HUP9902576A1 (hu) 1999-12-28
BR9707709A (pt) 1999-04-06
FR2745290B1 (fr) 1998-04-03
US6096714A (en) 2000-08-01
JP2000505469A (ja) 2000-05-09
CZ258798A3 (cs) 1998-12-16
HU227567B1 (en) 2011-08-29
AP952A (en) 2001-03-29
PL191736B1 (pl) 2006-06-30
EA001376B1 (ru) 2001-02-26
AU1929897A (en) 1997-09-16
EP0885234A1 (fr) 1998-12-23
CN1212700A (zh) 1999-03-31
IL125622A (en) 2003-10-31
NZ331600A (en) 1999-08-30
EE9800265A (et) 1999-02-15
NO983955L (no) 1998-08-27
UA58504C2 (uk) 2003-08-15
BG102691A (en) 1999-06-30
NO983955D0 (no) 1998-08-27
BR9707709B1 (pt) 2014-10-14
AR005999A1 (es) 1999-07-21
PT885234E (pt) 2002-10-31
KR100486053B1 (ko) 2005-06-16
DE69712610D1 (de) 2002-06-20
JP4102440B2 (ja) 2008-06-18
TR199801713T2 (xx) 1998-12-21
SK118498A3 (en) 1999-07-12
IL125622A0 (en) 1999-04-11
YU37098A (sh) 1999-07-28
ATE217633T1 (de) 2002-06-15
KR19990087324A (ko) 1999-12-27
FR2745290A1 (fr) 1997-08-29
ZA971659B (en) 1998-02-26
EP0885234B1 (fr) 2002-05-15
ES2176698T3 (es) 2002-12-01
CN1168734C (zh) 2004-09-29

Similar Documents

Publication Publication Date Title
DE69724142D1 (de) Sulfonamid-derivate, verfahren zur ihrer herstellung und ihre verwendung als arzneimittel
DE69712610T2 (de) Erythramicin-derivate, ihre verfahren zur herstellung und ihre verwendung als arzneimittel
ATE172203T1 (de) Erythromycinderivate, ihre verfahren zur herstellung und ihre verwendung als arzneimittel
ATE234853T1 (de) Erythromycin-derivate, verfahren zur herstellung und ihre verwendung als arzneimittel
ATE302754T1 (de) Sulfonylcarboxamidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE69131627D1 (de) Dialkoxypyridinylbenzimidazolderivate, verfahren zur herstellung und ihre pharmazeutische verwendung
DE59404480D1 (de) Fullerenderivate, verfahren zur herstellung und deren verwendung
DE59707976D1 (de) Neue guanidinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE232879T1 (de) Erythromycin-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
ATE245160T1 (de) Derivate von erythromycin, ihr verfahren zur herstellung, und ihre verwendung als arzneimittel
DE69618607D1 (de) Derivate von 5-0-desosaminyl-6-0-methyl erythronolid a, ihre verfahren zur herstellung und verwendung zur herstellung von arzneimitteln
DE59610963D1 (de) Neue phenylamidinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE69626682D1 (de) Verfahren zur herstellung von guanidinderivaten, zwischenprodukte dafür und ihre herstellung
ATE301645T1 (de) Polycyclische thiazolidin-2-yliden amine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE267811T1 (de) Substituierte 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin- 0-ole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE69901098D1 (de) Hypnotische beta-carbolin derivate verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE69716284D1 (de) Erythromycin-derivate, verfahren zur herstellung und verwendung als arzneimittel
ATE209212T1 (de) Aromatische ribose-substituierte derivate, verfahren zu ihrer herstellung und ihrer verwendung als arzneimittel
DE69712361T2 (de) Erythromycinderivate, verfahren zu ihrer herstellung, und ihrer verwendung als arzneimitteln
ATE224890T1 (de) Substituierte 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin- 0-ole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE59405814D1 (de) Neue leukotrien-b4-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE302766T1 (de) Polycyclische 2-amino-dihydrothiazolsysteme, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE59810800D1 (de) Benzylaminderivate und phenylethylaminderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE59902136D1 (de) Phenylethylaminderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE69521142D1 (de) 6-methoxy-1h-benzotriazol-5-carboxamid-derivate, verfahren zur herstellung und diese enthaltende arzneimittel

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN

8328 Change in the person/name/address of the agent

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, 80335 MUENC